Correspondence

Contents: Psychiatric morbidity and compulsory admission/The safety and efficacy of clozapine?/ Alzheimer's disease and Lewy body dementia/ Anorexic siblings/Neuroleptic malignant syndrome and carbamazepine.

Psychiatric morbidity and compulsory admission

SIR: One interesting but undiscussed finding of Thomas et al (BJP, July 1993, 163, 91-99) is of the low rate of admissions from ethnic minorities for non-psychotic disorders (see Table below). Further research on this topic would undoubtedly be valuable, although may be difficult to achieve in an area which grant-giving bodies are likely to perceive as unproblematic (Littlewood & Lipsedge, 1989).

Table to show rates of first admission and readmission for different ethnic groups

	Europeans	Asians	Afro- Carribbeans
Non-psychotic admissions	192	15	8
Non-psychotic readmissions	351	10	13
Populations at risk	48 624	4289	4679
Rate per 1000 non- psychotic admissions Rate per 1000 non-	3.95	3.44	1.71
psychotic readmissions	7.22	2.33	2.78

LITTLEWOOD, R. & LIPSEDGE, M. (1989) Aliens and Alienists: Ethnic Minorities and Psychiatry (2nd edn), p. 257. London: Unwin Hyman.

BERNARD INEICHEN

Charing Cross and Westminster Medical School 6th Floor, Laboratory Block Charing Cross Hospital London W6 8RE

AUTHORS' REPLY: Dr Ineichen's observation that the rate of admission for non-psychotic disorders among ethnic minority groups in Central Manchester (BJP, July 1993, 163, 91–99) is reduced in comparison to Europeans is correct. The table he has produced is

of collapsed data (abstracted from Table 3 of our paper, p 95), for all age groups by ethnic group. The 95% confidence intervals (Diem & Lentner, 1970) for each rate per year per 100 000 population for first admissions are: European 98.7 (84.3–112.6); Asian 87.4 (48.9–144.2); and Afro-Caribbean 42.7 (18.4–84.1)*. For readmissions the 95% confidence intervals are: European 180.5 (161.6–199.9); Asian 58.3 (28.0–107.2)*; and Afro-Caribbean 69.5 (37.0–118.9)*. (*indicates that the 95% confidence intervals are non-overlapping.)

Compared with Europeans, the rates of first admission for Afro-Caribbeans and readmission for Afro-Caribbeans and Asians are significantly reduced. Some caution must be exercised when interpreting these results because the number of subjects within each ethnic grouping was small and there were difficulties in estimating the various population denominators.

If these findings are not due to methodological error then it suggests that, in comparison with Europeans, ethnic minorities are either less prone to minor psychiatric morbidity or underuse or access psychiatric services differently (Brewin, 1980). We agree with Dr Ineichen that further research is necessary to establish the level of psychiatric morbidity among ethnic minorities and also that services may have to adapt to meet the needs of these different groups.

Brewin, C. (1980) Explaining the lower rates of psychiatric treatment among Asian immigrants in the United Kingdom: a preliminary study. Social Psychiatry, 15, 17-19.

DIEM, K. & LENTNER, C. (1970) Scientific tables. In *Documenta Geigy* (7th edn) (eds K. Diem & C. Lentner). Basle: Geigy.

CHRISTOPHER S. THOMAS

University Hospital of South Manchester Manchester M20 8LR

KIT STONE

Hope Hospital, Manchester

MADELINE OSBORN

Manchester Royal Infirmary, Manchester

PHIL THOMAS

Ysbyty Gwynedd, Bangor

The safety and efficacy of clozapine?

SIR: Since the Clozapine Study Group's paper showed that clozapine is both unsafe and ineffective, why is their report (BJP, August 1993, 163, 150-154)

entitled "The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK"?

Firstly, their 54 "treatment-resistant" patients were not so treatment-resistant. They had had on average five past schizophrenic episodes, which means they had five times previously got better, to a greater or lesser extent, in response to treatment or without it. Furthermore, a number of unspecified patients were responding to pre-existing medication. Some were so "partially controlled" that it could only be gradually withdrawn and replaced by clozapine, and a few were "permitted" to stay on it and receive clozapine "in parallel" throughout the trial.

Then, the therapeutic results were, to say no more, unimpressive. Over half the cases (28) were outright failures and did not complete the six-month course: one because of suicide; 15 (28%) because they were "uncooperative" or "violated the protocol", which implied they remained too ill to accept clozapine, or retained enough sanity to refuse it; four because "the study drug was ineffective"; and seven (13%) because of adverse reactions.

In ordinary language, these *are* outright failures, even though the authors prefer to gloss over them as "early terminations". Of the remaining 26 cases, 19 were still, after six months, "moderately" or "markedly" or "severely" ill, and only 7 (12% of the whole series) had become "borderline or mildly ill". And of these 26, epileptic seizures developed in five.

Undaunted, the Study Group concludes that these results are "highly encouraging." They even contend, and this after only six months' observation, that their results "clearly show" that clozapine can have *long-term* benefits for these patients! Were that true, or even plausible, it would have made headlines long ago, since clozapine has been in use for 30 years (McKenna & Bailey, BJP, January 1993, 162, 32–37).

They should re-examine the forgotten story of insulin coma therapy in schizophrenia (Bourne, 1953; Cramond, 1987). It too was a breakthrough, it too was dangerous as well as extremely costly and, in its heyday of universal use, it produced results far superior to these. And yet, in the end, it was an illusion.

BOURNE, H. (1953) The insulin myth. Lancet, 2, 964.
CRAMOND, W. A. (1987) Lessons from the insulin story in psychiatry. Australian and New Zealand Journal of Psychiatry, 21, 320.

HAROLD BOURNE

Via M. Bragadin, 6 00136 Roma Italy

Alzheimer's disease and Lewy body dementia

SIR: In reference to our study (Förstl et al, BJP, March 1993, 162, 385-392) Liberini et al (BJP, November 1993, 163, 693-694) raise the possibility that responders to cholinesterase inhibitors, and in particular to tacrine, may turn out to show Lewy body pathology. They suggest that the solution to this might come from a post-mortem examination of responders.

As our own tacrine trial was the first to identify the presence of a subgroup of responders, constituting about one-third of those entering the study (Eagger et al, 1991), we have, where possible, attempted to carry out such a post-mortem follow-up. Since only a proportion of all patients maintained contact with our unit in order to obtain continued supplies of tacrine after the cessation of the trial, the sample under such study is liable to be biased. However, it is worth reporting that the first three brains studied, all from 'responders', did indeed show a considerable number of cortical Lewy bodies in addition to numerous plaques, tangles and β-amyloid deposits. Where it proved possible to obtain frozen tissue from the brains (in two out of the three cases) cholinacetyltransferase levels measured in Dr Elaine Perry's laboratory were found to be even lower than those in pure Alzheimer's disease.

Thus, although it is too early to reach a definite conclusion on the limited number of post-mortems carried out so far, preliminary results suggest that Liberini et al's prediction may well turn out to be correct.

EAGGER, S., LEVY, R. & SAHAKIAN, B. (1991) Tacrine in Alzheimer's disease. Lancet, 337, 989-992.

RAYMOND LEVY

Institute of Psychiatry De Crespigny Park Denmark Hill London SE5 8AF

Anorexic siblings

SIR: It is generally agreed that anorexia nervosa has a multi-determined aetiology (Garfinkel & Garner, 1982) and intrafamilial factors are rightly regarded as of particular importance (Hsu, 1990). Close attention is usually paid to the relationship between the sufferer and his/her parents (for example, see Bruch, 1988). I suspect, admittedly on anecdotal grounds, that the effects of siblings on each other may also be of importance, and recent considerable media publicity surrounding the 'diet twins' (for example, Sunday Mirror, 19 September 1993, p. 24: "Story all